Shares of IMV Inc. (NASDAQ:IMV) have received a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $8.54.
Several research analysts have commented on IMV shares. National Bankshares lowered their price objective on shares of IMV from $7.00 to $5.25 and set a “sector perform” rating for the company in a research report on Thursday, March 18th. Leede Jones Gab restated a “speculative buy” rating on shares of IMV in a research report on Thursday, March 18th. Raymond James reiterated a “market perform” rating and set a $3.00 price target on shares of IMV in a report on Thursday, March 18th. Finally, Zacks Investment Research downgraded shares of IMV from a “hold” rating to a “sell” rating in a report on Thursday, February 4th.
Several hedge funds have recently added to or reduced their stakes in IMV. VR Adviser LLC bought a new position in shares of IMV during the 3rd quarter worth about $17,760,000. Letko Brosseau & Associates Inc. bought a new position in shares of IMV during the 4th quarter worth about $519,000. Renaissance Technologies LLC boosted its position in shares of IMV by 508.3% during the 4th quarter. Renaissance Technologies LLC now owns 110,100 shares of the company’s stock worth $338,000 after purchasing an additional 92,000 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of IMV by 31.8% in the 3rd quarter. Wells Fargo & Company MN now owns 368,838 shares of the company’s stock worth $1,637,000 after acquiring an additional 88,948 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of IMV in the 4th quarter worth about $190,000. 20.74% of the stock is currently owned by institutional investors.
Shares of NASDAQ:IMV traded down $0.06 during trading on Monday, reaching $2.90. 4,800 shares of the stock were exchanged, compared to its average volume of 283,236. IMV has a 12 month low of $1.50 and a 12 month high of $6.82. The firm has a market cap of $196.12 million, a PE ratio of -6.43 and a beta of 1.69. The stock has a 50-day moving average price of $3.39 and a 200-day moving average price of $3.43. The company has a current ratio of 7.03, a quick ratio of 7.03 and a debt-to-equity ratio of 0.20.
IMV (NASDAQ:IMV) last issued its quarterly earnings results on Tuesday, March 16th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. IMV had a negative return on equity of 180.04% and a negative net margin of 9,661.54%. On average, sell-side analysts expect that IMV will post -0.36 earnings per share for the current fiscal year.
IMV Company Profile
IMV Inc operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities.
Featured Story: What is a short straddle?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.